RELATED BETWEEN HISTORY ALLERGTIEENSAND PROCESS OF DENGUE HEMORRHAGIC FEVER

Description of Topic BASIC SCIENTIFIC RESEARCH Dengue hemorrhagic fever is a infectious disease by mosquitoes Ades aegypti, derived from approximately 500 to 600 years in Africa before 6. Dengue hemorrhagic fever can spread into an epidemic diseases in the tropics and subtropics, and affects 120 countries, where 2.5 billion people live in urbanized areas 6, 7. There are over 390 million are infected with dengue hemorrhagic fever worldwide every year and about 96 million people have symptoms for more than 22,000 deaths. Dengue hemorrhagic fever has diverse manifestations, from asymptomatic infections can be mild, selflimiting to exit the plasma cause complications, coagulopathy, thrombocytopenia, bleeding, multibody injury agencies can lead to death 3, 8. Currently, there is no vaccine and specific treatment for dengue hemorrhagic fever. According to the World Health Organization (2009), Dengue infections are classified as dengue hemorrhagic fever, dengue hemorrhagic fever warning signs, severe dengue hemorrhagic fever: Dengue hemorrhagic fever shock, multiple organ damage such as liver damage, kidney, brain inflammation 6 ... dengue hemorrhagic fever can be diagnosed based on clinical symptoms and changes in hematocrit, platelets and definitive diagnosis in some cases by NS1 or IgM or RTPCR reaction 1.

Description of Topic BASIC SCIENTIFIC RESEARCH I GENERAL INFORMATION OF NAME RELATED BETWEEN HISTORY ALLERGTIEENSAND PROCESS OF DENGUE HEMORRHAGIC FEVER Code TIME (FROM 09/2016 TO 09/2017 ) EXPENSE TOTAL; FROM : FUND SNKH Code Chairman Full Name: Nguyen Thi Cam Huong Academic Rank/Degree: Master - MD Title of science: Phone :0838382214 (CQ)/ 0837754603 (NR) Mobile: 0983773915 E-mail: camhuong37@yahoo.com Office's address: 764 Vo Van Kiet St, Ward 1, District 5, HCMC Fax: Address: 333 Nguyen Trai St, Ward 7, district 5, HCMC Organism in charge: ( organization of Science and Technology): Tropical Disease Hospital Phone: Fax: E-mail: Address: 764 Vo Van Kiet, Ward 1, District 5, Ho Chi Minh city *Note: In the case of organizations and individuals, who need a better presentation for some certin item of this presentation, that may be longer, but the total of pages of the presentation mustn't exceed 20 pages (No matter the budget appendix topic) II The purpose of object  Overall object: describe the progress indengue hemorrhagic fever in two groups of patients with and without allergic history  Specific object: • Compare the ratio of types of dengue hemorrhagic fever in two groups of patients with and without allergic history • Compare the degree of thrombocytopenia, bleeding, blood concentration and purpuric rash that recover between two groups of patients with and without allergic history • 10 Compare the rate of dengue hemorrhagic fever in two groups of patientswith and without using Allergy and Asthma Drug Research situation in Vietnam and Abroad Status of research New Continuation of previous research Overview of document in the field of research Dengue hemorrhagic fever is a infectious disease by mosquitoes Ades aegypti, derived from approximately 500 to 600 years in Africa before [6] Dengue hemorrhagic fever can spread into an epidemic diseases in the tropics and subtropics, and affects 120 countries, where 2.5 billion people live in urbanized areas [6], [7] There are over 390 million are infected with dengue hemorrhagic fever worldwide every year and about 96 million people have symptoms for more than 22,000 deaths Dengue hemorrhagic fever has diverse manifestations, from asymptomatic infections can be mild, self-limiting to exit the plasma cause complications, coagulopathy, thrombocytopenia, bleeding, multi-body injury agencies can lead to death [3], [8] Currently, there is no vaccine and specific treatment for dengue hemorrhagic fever According to the World Health Organization (2009), Dengue infections are classified as dengue hemorrhagic fever, dengue hemorrhagic fever warning signs, severe dengue hemorrhagic fever: Dengue hemorrhagic fever shock, multiple organ damage such as liver damage, kidney, brain inflammation [6] dengue hemorrhagic fever can be diagnosed based on clinical symptoms and changes in hematocrit, platelets and definitive diagnosis in some cases by NS1 or IgM or RT-PCR reaction [1] The reason why Dengue infection could progress hasn’t been explored out, the exploring factors that make worse reduces disease burden caused by Dengue virus Several factors such as secondary Dengue infection by multiple serotypes different are proven According to the WHO and the recent studies, there are many risk factors that increase the likelihood of developing severe dengue disease such as age, asthma, allergies , malnutrition, obesity, diabetes, hypertension In Dengue infection, mast cells are activated and release seeds, increased histamine and other mediator inflammatory chemicals Therefore, the histamine antagonists play an important role in sustainable mast cells for patients who infected with dengue and reduce the risk of developing severe dengue infection by asthma and allergic risk factors Corticoides influence and Dengue disease progression have not been clearly demonstrated In patients with dengue, electronic original appearance of recovery from 6th day of the disease as a manifestation of allergic reaction to the changing expression with many different levels such as red skin, or death at point-density board thick on the skin redness, itching from little more soles So researchers wanted to find out the role of allergic illness affects how the disease progresses to dengue References Capeding MR, C M., Hadinegoro SR, et al (2013) Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children PLoS Negl Trop Dis, 7(7), e2331 DJ., G (1998) Dengue and dengue hemorrhagic fever Clinical microbiology reviews 11(3), 480-496 • • S.B, H (2007) Dengue The Lancet, 370(9599), 1644-1652 Sanchez, L F., Hotta, H., Hotta, S & Homma, M (1986) Degranulation and Histamine Release from Murine Mast Cells Sensitized with Dengue Virus‐Immune Sera Microbiology and immunology, 30(8), 753-759 Teixeira MdG, C M., Barreto ML, Mota E (2005) Dengue and dengue hemorrhagic fever epidemics in Brazil: what research is needed based on trends, surveillance, and control experiences? Cadernos de saude publica, 21(5), 1307-1315 WHO (2009) Dengue: guidelines for diagnosis, treatment, prevention and control Wilder-Smith A, G D J (2008) Geographic expansion of dengue: the impact of international travel Medical Clinics of North America, 692(6), 1377-1390 Wills BA, D N., Loan HT, et al (2005) Comparison of three fluid solutions for resuscitation in dengue shock syndrome New England Journal of Medicine, 353(9), 877-889 Zhang, F K., C V (2014) Corticosteroids for dengue infection The Cochrane Library, 10(5), e00045755 How to approach, research methods, techniques will be used (indicate clearly that how to approach, design the research, how to select a sampling, sample size, criteria to be selected of research subject, research methods, techniques will be used- comparing with similar modes settlement other, research criteria, technical facilities, and equipments to determine researched criteria, indicating new features, interested features, creative features of this study method Design: interrupted description Samples: The patient of Dengue fever are treated in the hospital Place and time of research: Falcuty infection C and D, Falcuty Antitrust resuscitation adults, falcuty pediatrics A, falcuty antitrust reuscitation children from 9/2016 to 9/2017 Sample size: All of patients were admitted to falcuties which was indicated above in one year Population: All of patients were diagnosed Dengue fever Criteria to select: - The Dengue haemorrhagic fever’s patient is diagnosed by NS1 (+) or IgM anti Dengue, or clinical symptoms is diagnosed (NS1 or IgM test isn’t done) after excluding orther causes of haemorrhagic fever: fever, symptoms of viral infections, liver enlargement and pain, mucosal bleeding, increase in Hct (more 20%) concurrent with rapid decrease in platelet count (less 100.00/mm3 ), clinical fluid accumulation (pleural and peritoneal fluid), rash recover from day 6th of disease Criteria to exclude: - The patient’s fever from other causes - The patient refuse to participate in research - The patient with HIV/AIDS 11 Variables: Background variables: age, gender, BMI, history of allergic symptoms, background diseases as diabetes, hypertension, a history of using antihistamine like ketotifen, corticoides, certirizine… during two weeks before the start of fever - The kinds of Dengue haemorrhagic fever according to the classification of WHO 2009 : o Dengue haemorrhagic fever: fever, muscular pain, a stiff joint, rash, nause, vomit, a decrease in leukocyte o Dengue haemorrhagic fever with warning signs: pain of right hypochondriac, more vomitting, clinical fluid accumulation, haemorrhagic mucosa, lethargy, restlessness, liver enlargement more cm, a increase in hematocrit and rapid decrease in platelet Severe Dengue haemorrhagic fever: severe plasma leakage: shock, fluid accumulation with respiratory distress, severe bleeding; damaging organs involve: damage liver with AST, ALT > 1000 IU/ml, Brain: impaired consciousness, myocarditis and damage other organs - History of allergy: When one of following diseases: asthma, food allergies, drug allergies, allergic rhinitis, urticaria recurrent, itchy skin, eczema,… - The level of mucosal bleeding: o Mild: Rash, dental bleeding, noisebleed less own haemostatic, Don’t need to blood and platelet tranfusion o Moderate: noisebleed with moderate level, not affect vital signs, don’t need to insert meche to stop bleeding, , ozzing dental bleeding is not affect vital signs o Severe: continous mucosal bleeding, affect to vital signs, need to blood and platelets tranfusion - The level of blood concentration: haven’t blood concentration (Hct< 20%), have blood concentration with moderate level (Hct>20%, no shock), severe blood concentration (Hct>20%, shock) - The level of decreased platelets: mild (platelets: 50.000-100.000/mm 3), moderate (platelets: 20.000-50.000/mm3), severe (platelets less 20.000 mm3) - The evolution of recovering rash: itchy skin+ a few of rash; redness of skin very much, itchy of skin+ rash the far of limb+body * Process: Dengue haemorrhagic fever’s patient is diagnosed determined by NS1(+) hay IgM anti Dengue (+), or have clinical symptoms is diagnosed Dengue haemorrhagic fever (can not complete NS1 and IgM test) after excluding the other causes of fever is selected into reseach The patients will be asked about history of allergic diseases, the using of antihistamine drugs like ketotifen, centicertirizine, corticoides during two weeks before the start of fever These patients will be followed clinical evolution during priod of time from to days until comeback home, the level of haemorrhage, of decreased platelets, of blood concentration, appear and evolute of recovering rash The rate of Dengue haemorrhagic fever, Dengue haemorrhagic with warning symptoms, severe Dengue haemorrhagic fever, the level of haemorrhage, of decreased platelets, of blood concentration, the evolution of recovering rash is compared between groups involved two groups have and haven’t history of allergic diseases, and two groups have and haven’t use antihistamines, corticoides o 12 Reasearch content (listed and described the contents which need to be studied, highlighting new and appropriate contents to address the questions, addressing research objectives was set out before, including expected operational coordination to transfer research results to users) Patients were diagnosed dengue admission will be recognized diagnosis, classification dengue discharge, bleeding levels, thrombocytopenia, blood concentration, expression and progression of recovery Percentage distribution of dengue, dengue warning signs, severe dengue, dengue extent and severity of thrombocytopenia, blood concentration level, progress of recovery was compared between the groups with and without a history of allergic diseases, groups with or without the use of antihistamines, corticosteroids The comparison between the two groups to determine the effects of a history of allergic diseases affecting the progression and severity dengue 13 International cooperation Partner (name) Content cooperation Cooperated Expected cooperation 14 Progress of implementation TT The contents, work mainly (The main benchmarks) Products must achieve Time (BĐ-KT) Persons ,implementin g agency III The results of the research 15 The expected results of the research I II 1* Samples (Model, maket) 2* Process technology 4* Product (finished or semi5* Method 3* III Diagrams 6* Table data finished products) 7* 10* 13* Material Equipment and machinery Technological lines 15* Drugs 17* 19* Vaccine Biology products 16 Order number 1 8* 11* Standard Rules Analysis Report Document forecasts 14* The scheme, planned deployment 16* Justifying the economictechnical, feasibility study 18* Computer program 20* Other (journal articles, training research students, students, ) 9* 12* Scientific requirements for product creation (Results form II, III) Product Scientific Request (Name) Note 17 Order number Technical requirements, quality standards for products created (result form I) Product names and principal quality indicators main Unit of measure Quality levels Expect ed Similar samples Domestic Expecte d to Number of products World 18 Method of transferring research results (Outlined stability of technological parameters, the customer address and describes method transfer of the results…) The impact of the research results (in addition the impact referred to in item 18 above) 1* Fostering and training of scientific and technological: increasing scientific research of the clinicians, training graduate students 2* For scientific fields related: identifying relevant possible between allergies and disease progression dengue 3* For economy - society: 19 IV The organizations / personal involved in the topic Activities of the organizations participating in implement the topic (Remember all the organization to implement the project and content of work participated in the topic) Order number Organization Address Activities / contributions to topic 20 21 22 Linked to production and life (Specifies the unit of production or those who use of research results participate in the implementation process and specify the content of work performed in topic) Staff to implement the topic Order number Full name A Head of research Nguyen Thi Cam Huong B Staff participate in study Agency work Faculty of infection D, YDS Percentage% of the time worked for the topic 40% Faculty of infection D 7% Specialist Nguyen Thanh Truong MSc Nguyen Thi Hong Lan MSc Nguyen Van Hao MSc Tran dang Khoa MSc Phan Tu Qui ThS Phạm kim Oanh 7% 9% MSc Le Thi thuy Hang Specialist Cao Tam Faculty of infection C 7% HSCCTCCĐ NL 7% Faculty of infection, YDS HSCCTCCĐ TE Faculty of infection, YDS Faculty of infection, YDS Faculty of pediatric A 7% 9% 7% V Funding to implement the project and budget (a detailed explanation please see attached appendix) Unit: million VND 23 Order numbe r 1 Funding to implement the project by spending Source of costs Total Detail Hiring Materials, energy Equipmen t Constructon, minor repairs Other Total costs: Detail: Fund of SNKH Source of costs other - Seft-suficient - Capital other: ., Superior Departament concerned of topic (first, last name, signed and stamp) Day month Head of research (first, last name and signed) year 201